CN103349664A - 含甾族的c-17苯并吡咯的组合物 - Google Patents

含甾族的c-17苯并吡咯的组合物 Download PDF

Info

Publication number
CN103349664A
CN103349664A CN2013101036754A CN201310103675A CN103349664A CN 103349664 A CN103349664 A CN 103349664A CN 2013101036754 A CN2013101036754 A CN 2013101036754A CN 201310103675 A CN201310103675 A CN 201310103675A CN 103349664 A CN103349664 A CN 103349664A
Authority
CN
China
Prior art keywords
compound
treatment
compounds
diene
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013101036754A
Other languages
English (en)
Chinese (zh)
Inventor
A·布罗迪
V·恩雅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland, College Park
Original Assignee
University of Maryland, College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland, College Park filed Critical University of Maryland, College Park
Publication of CN103349664A publication Critical patent/CN103349664A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2013101036754A 2005-03-02 2006-03-02 含甾族的c-17苯并吡咯的组合物 Pending CN103349664A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
US60/657,390 2005-03-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800064632A Division CN101155823A (zh) 2005-03-02 2006-03-02 新的c-17-杂芳基甾族的cyp17抑制剂/抗雄激素物质：其合成，体外生物学活性，药代动力学和抗肿瘤活性

Publications (1)

Publication Number Publication Date
CN103349664A true CN103349664A (zh) 2013-10-16

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2013101036754A Pending CN103349664A (zh) 2005-03-02 2006-03-02 含甾族的c-17苯并吡咯的组合物
CNA2006800064632A Pending CN101155823A (zh) 2005-03-02 2006-03-02 新的c-17-杂芳基甾族的cyp17抑制剂/抗雄激素物质：其合成，体外生物学活性，药代动力学和抗肿瘤活性

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006800064632A Pending CN101155823A (zh) 2005-03-02 2006-03-02 新的c-17-杂芳基甾族的cyp17抑制剂/抗雄激素物质：其合成，体外生物学活性，药代动力学和抗肿瘤活性

Country Status (21)

Country Link
US (1) US7875599B2 (cg-RX-API-DMAC7.html)
EP (2) EP2206719B1 (cg-RX-API-DMAC7.html)
JP (2) JP5130453B2 (cg-RX-API-DMAC7.html)
KR (1) KR101380959B1 (cg-RX-API-DMAC7.html)
CN (2) CN103349664A (cg-RX-API-DMAC7.html)
AT (1) ATE482969T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006218711B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0607523A2 (cg-RX-API-DMAC7.html)
CA (1) CA2599953C (cg-RX-API-DMAC7.html)
DE (1) DE602006017175D1 (cg-RX-API-DMAC7.html)
DK (2) DK2206719T3 (cg-RX-API-DMAC7.html)
EA (1) EA019560B1 (cg-RX-API-DMAC7.html)
ES (2) ES2528055T3 (cg-RX-API-DMAC7.html)
IL (3) IL185608A (cg-RX-API-DMAC7.html)
MX (1) MX2007010593A (cg-RX-API-DMAC7.html)
NZ (1) NZ561571A (cg-RX-API-DMAC7.html)
PL (2) PL1853619T3 (cg-RX-API-DMAC7.html)
PT (2) PT1853619E (cg-RX-API-DMAC7.html)
SI (2) SI2206719T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006093993A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708106B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
JP5130453B2 (ja) * 2005-03-02 2013-01-30 ユニバーシティ オブ メリーランド，ボルティモア 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009120565A2 (en) * 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
BRPI0920681A2 (pt) * 2008-10-28 2015-12-29 Biomarin Pharm Inc inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17
EP2393827B1 (en) * 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
GB2479693B (en) * 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
WO2010091299A2 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel combination cancer therapies
PE20121048A1 (es) 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
EP2461814A4 (en) * 2009-08-07 2012-12-05 Tokai Pharmaceuticals Inc PROSTATE CANCER TREATMENT
AU2010319697B2 (en) * 2009-11-13 2016-05-19 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
BR112013017635A2 (pt) * 2010-12-16 2016-10-11 Biomarin Pharm Inc inibidores de cyp11b, cyp17 e/ou cyp21
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2014165815A2 (en) * 2013-04-04 2014-10-09 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
KR20160058774A (ko) * 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
ES2700901B2 (es) * 2016-08-08 2019-08-06 Ind Chimica Srl Proceso para la preparación de 3ß-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno.
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
AU2019222651B2 (en) * 2018-02-13 2024-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
EP3752517B1 (en) * 2018-02-13 2025-04-09 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
AU2020393896A1 (en) 2019-11-26 2022-06-23 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (cg-RX-API-DMAC7.html) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
PT1660115E (pt) 2003-07-29 2011-08-24 Dompe Spa ASSOCIAÇÃO FARMACjUTICA DE G-CSF E DE PLGF ÚTIL NA MOBILIZAÇÃO DE CÉLULAS ESTAMINAIS DO SANGUE
JP5130453B2 (ja) 2005-03-02 2013-01-30 ユニバーシティ オブ メリーランド，ボルティモア 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OMOSHILE O. CLEMENT ET AL: "Three Dimensional Pharmacophore Modeling of Human CYP17 Inhibitors.Potential Agents for Prostate Cancer Therapy", 《J. MED. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法

Also Published As

Publication number Publication date
JP2008536807A (ja) 2008-09-11
US20080280864A1 (en) 2008-11-13
MX2007010593A (es) 2008-02-20
DK2206719T3 (en) 2015-01-26
DK1853619T3 (da) 2011-01-10
PT2206719E (pt) 2015-02-05
JP2012255026A (ja) 2012-12-27
KR101380959B1 (ko) 2014-04-04
AU2006218711A1 (en) 2006-09-08
IL210480A0 (en) 2011-03-31
IL185608A (en) 2016-06-30
ES2528055T3 (es) 2015-02-03
IL210480A (en) 2015-06-30
ATE482969T1 (de) 2010-10-15
AU2006218711A2 (en) 2006-09-08
IL210478A0 (en) 2011-03-31
IL185608A0 (en) 2008-01-06
EP1853619A4 (en) 2009-08-26
KR20070120119A (ko) 2007-12-21
PL1853619T3 (pl) 2011-03-31
EP2206719A3 (en) 2011-01-05
PT1853619E (pt) 2011-01-03
EA019560B1 (ru) 2014-04-30
EP2206719A2 (en) 2010-07-14
EP1853619B1 (en) 2010-09-29
PL2206719T3 (pl) 2015-03-31
EA200701872A1 (ru) 2008-06-30
US7875599B2 (en) 2011-01-25
SI2206719T1 (sl) 2015-03-31
EP1853619A1 (en) 2007-11-14
JP5613206B2 (ja) 2014-10-22
EP2206719B1 (en) 2014-10-22
DE602006017175D1 (de) 2010-11-11
HK1115387A1 (en) 2008-11-28
CA2599953C (en) 2013-08-13
ZA200708106B (en) 2008-12-31
CA2599953A1 (en) 2006-09-08
JP5130453B2 (ja) 2013-01-30
NZ561571A (en) 2009-09-25
CN101155823A (zh) 2008-04-02
SI1853619T1 (sl) 2011-01-31
AU2006218711B2 (en) 2010-11-11
BRPI0607523A2 (pt) 2009-09-08
WO2006093993A1 (en) 2006-09-08
ES2353413T3 (es) 2011-03-01

Similar Documents

Publication Publication Date Title
JP5613206B2 (ja) 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性
US10098896B2 (en) C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Handratta et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
ZA200700958B (en) Novel 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17pMiydroxysteroid dehydrogenase type I
KR20150036319A (ko) 3-치환된 에스트라-1,3,5(10),16-테트라엔 유도체, 그의 제조방법, 이를 포함하는 약학 제제 및 의약품 제조를 위한 그의 용도
CA2780365A1 (en) Mammalian metabolites of steroids
CA2978454A1 (en) Altering steroid metabolism for treatment of steroid-dependent disease
US7732493B2 (en) 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
SK40895A3 (en) 17-beta-substituted 4-azaandrostane derivatives, pharmaceutical compositions containing them and process for preparing same
HK1115387B (en) 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease
CZ300376B6 (cs) Ligandy estrogenových receptoru alfa a beta, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
Salvador et al. Treatment: From Concept to Clinic

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20131016